Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q3 2025 · 10-Q
Revenue$12.88M$12.88M+43.7% vs Q3 2024 Net Income-$103.43M-$103.43MN/M vs Q3 2024 EPS Diluted-$1.78-$1.78N/M vs Q3 2024 Operating Income-$116,869,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$89,706,000N/M Margins · derivedOperating margin-907.4%+239.6 pt vs Q3 2024
Net margin-803.1%
ended Sep 30, 2025 · filed Oct 30, 2025 · 30 d after period end